Improving HIV Prevention Services among Socioeconomically Disadvantaged Cis-gender Women
Improving HIV Prevention Services among Socioeconomically Disadvantaged Cis-gender Women
批准号:
10677044
负责人:
Jenell S Coleman
金额:
$79.84万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
未结题
起止时间:
2022-08-05 至 2027-05-31
关键词:
AIDS preventionAffectAssessment toolBaltimoreBlack raceCaringCitiesClinicClinicalClinical TrialsCollaborationsCommunicationCounselingData CollectionDisclosureEducationElectronic Health RecordElectronicsEligibility DeterminationEpidemicEquityEvidence based interventionFemaleFumaratesFundingGoalsHIVHIV InfectionsHIV riskHealth BenefitHealth systemHeterosexualsHuman immunodeficiency virus testHybridsIncidenceInterventionInvestmentsKnowledgeLocal GovernmentMarketingMarylandMedicaidMethodsMultimediaOffice VisitsOralPatientsPopulationPrenatal carePrevalenceProviderPublic HealthRandomizedReach, Effectiveness, Adoption, Implementation, and MaintenanceRecording of previous eventsReportingReproductive Health ServicesRiskRisk AssessmentRisk FactorsSelf AdministrationSexual HealthSexually Transmitted DiseasesSiteSurveysTechnologyTenofovirTimeUnited StatesUnited States Health Resources and Services AdministrationWomananimationarmblack womenbudget impactcare deliverycis-femaleclinical carecomputerizedcondomsconsistent condom usecontextual factorscostcost-effectiveness evaluationdisadvantaged womendisease transmissioneffective interventioneffectiveness-implementation RCTemtricitabinehigh riskimplementation strategyimprovedmalemedical specialtiesmenmen who have sex with menmulti-component interventionpatient populationpatient-level barrierspre-exposure prophylaxispreferenceprevention serviceprimary outcomeprovider interventionprovider-level barriersrisk perceptionservice deliverysexsexually activesocioeconomic disadvantagestandard of caretooluptake
中文摘要
点击翻译按钮获取中文摘要
英文摘要
ABSTRACT
Nearly one out of five new HIV infections in the United States occurs among cisgender women, with 85% of
cases attributed to heterosexual contact. Black women are disproportionately affected, comprising 60% of new
HIV infections among women, although they comprise only 14% of the female population. Consistent condom
use, daily oral tenofovir disoproxil fumarate 300mg-emtricitabine 200mg (TDF-FTC) as pre-exposure prophylaxis
(PrEP), and male partner HIV testing are evidence-based interventions for women to reduce their risk of HIV
acquisition. Yet, only 1-6% of women who could benefit from PrEP are prescribed it. Barriers to PrEP uptake are
multifactorial. Patient-level barriers to PrEP uptake include women who may not think PrEP is for them, given
that the majority of PrEP clinical trials and marketing strategies have targeted men who have sex with men. Also,
cisgender women may not perceive themselves as being at risk for HIV. Further exacerbating the discordance
between risk perception and actual risk is that women tend to be unaware of their male partners' HIV serostatus
and HIV risk factors. Provider-level barriers include difficulty identifying patients at high risk for HIV, discomfort
with sexual history taking, and lack of PrEP knowledge. Unfortunately, an accurate HIV risk assessment tool
does not exist for U.S. cisgender women and may not ever exist because the HIV incidence in U.S. women is
too low to develop it. An alternative evidence-based intervention is desperately needed. We plan to fill this gap
by identifying an effective intervention and implementation strategy to increase PrEP uptake in an ObGyn clinical
setting (where women receive prenatal care and sexual and reproductive health services). Since TDF-FTC was
approved, women have consistently expressed a preference for receiving HIV prevention services in clinics
where they receive ObGyn care. Our multi-level (patient and provider-level), multi-component intervention
includes EHR data collection and education using multi-media tools. Our central hypothesis is that
communicating tailored HIV risk messaging in real-time in a relatable and comprehensive manner to patients
and ObGyn providers can increase conversations about HIV prevention. Aim 1A: To determine the most
effective intervention and evaluate its implementation in an ObGyn clinical setting. 1B: To identify modifiable
contextual factors associated with effective implementation using the RE-AIM framework. Aim 2: To evaluate
the cost-effectiveness, return on investment, budget impact, and equity impact of the multi-level intervention
components and the implementation strategy. In collaboration with our local government- and a HRSA-funded
implementing partner sites, we hope to demonstrate a sustainable and scalable solution to increasing PrEP
counseling by ObGyn providers and PrEP uptake by patients.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Improving HIV Prevention Services among Socioeconomically Disadvantaged Cis-gender Women
-
批准号:10459650
-
项目类别:
-
资助金额:$82.59万
-
财政年份:2022
-
负责人:Jenell S Coleman
-
依托单位:
Improving HIV Prevention Services among Socioeconomically Disadvantaged Cis-gender Women
-
批准号:10772735
-
项目类别:
-
资助金额:$21.62万
-
财政年份:2022
-
负责人:Jenell S Coleman
-
依托单位:
Inflammation, Vaginal Microbiota, and STI/HIV Risk
-
批准号:9910583
-
项目类别:
-
资助金额:$22.93万
-
财政年份:2019
-
负责人:Jenell S Coleman
-
依托单位:
“Inflammation, Vaginal Microbiota, and STI/HIV Risk”
-
批准号:9908138
-
项目类别:
-
资助金额:$47.27万
-
财政年份:2017
-
负责人:Jenell S Coleman
-
依托单位:
“Inflammation, Vaginal Microbiota, and STI/HIV Risk”
-
批准号:9333796
-
项目类别:
-
资助金额:$49.01万
-
财政年份:2017
-
负责人:Jenell S Coleman
-
依托单位:
海外基金